Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01131039
Recruitment Status : Withdrawn (PI left Emory)
First Posted : May 26, 2010
Last Update Posted : December 20, 2013
Genentech, Inc.
Information provided by (Responsible Party):
Emory University

Brief Summary:
The purpose of the study is to determine whether the administration of bevacizumab and gemcitabine given by IV infusion can prolong survival, delay tumor growth, and/or shrink tumors in patients with ovarian cancer, primary peritoneal, or fallopian tube cancer.

Condition or disease Intervention/treatment Phase
Fallopian Tube Neoplasms Ovarian Cancer Primary Peritoneal Drug: Gemcitabine/Bevacizumab Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Study Start Date : January 2011
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011

Arm Intervention/treatment
Experimental: Single Drug: Gemcitabine/Bevacizumab

Gemcitabine: IV, days 1,8, and every 21 days

Bevacizumab: IV, day 1 and every 21 days until disease progression

Other Names:
  • Gemcitabine
  • Gemzar®
  • Bevacizumab
  • Avastin

Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: 2 years ]
    The primary outcome measure is progression-free survival. Disease status and response rates will be determined by investigator assessment using RECIST or CA-125 changes (subjects with nonmeasurable disease only)

Secondary Outcome Measures :
  1. Safety and tolerability of bevacizumab in combination with gemcitabine will be assessed. [ Time Frame: 2 years ]

    The safety and tolerability of bevacizumab in combination with gemcitabine will be assessed using the following measures:

    - Incidence, nature, severity, and relatedness of adverse events graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE, Version 3.0)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must have platinum-resistant ovarian, primary peritoneal or fallopian tube cancer.

Patients will be included in the study based on the following criteria:

  1. Signed informed consent
  2. Age ≥ 19 yrs
  3. Advanced, histologically documented ovarian, primary peritoneal, or fallopian tube cancer
  4. Measurable disease with at least one lesion that can be accurately measured in at least one dimension (longest dimension recorded). Each lesion must be > 20 mm when measured by conventional techniques, including palpation, plain x-ray, CT and MRI, or > 10 mm when measured by spiral CT. OR Clinically or radiologically detectable disease (ascites, peritoneal deposits, mesenteric thickening or lesions that do not fulfill RECIST for measurable disease). In addition, the subject must have two consecutive rising pretreatment CA-125 levels that are both > 2x the institutional upper limit of normal (ULN) and 40.0 IU/ml taken at least 1 week and nor more than 3 months apart.
  5. Platinum-resistant or refractory cancer; subjects must not have had a biologic or chemotherapeutic regimen for treatment of platinum-resistant disease prior to study entry. Subjects with primary platinum-resistant cancer must have had a tumor recurrence within 6 months after completing or while receiving a platinum-containing regimen. These subjects must not have had any other non-platinum-containing regimen. OR Subjects with secondary platinum-resistant cancer may have had any regimen with any response and then have had tumor recurrence within 6 months after completing or while receiving retreatment with a platinum-containing regimen. These subjects must have received only two prior chemotherapeutic regimens. OR Subjects who receive a chemotherapeutic regimen as consolidation after a response to a platinum-containing regimen must have had tumor recurrence within 6 months after completing or while receiving the consolidation regimen.
  6. Life expectancy > 12 weeks
  7. ECOG performance status 0 or 1
  8. Use of an effective means of contraception (for women of childbearing potential)
  9. Clinical laboratory test results: Granulocyte count > 1500/µL; Platelet count > 75000/µL; Hemoglobin > 9g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbepoetin is permitted); Serum bilirubin < 1.5 the ULN; alkaline phosphatase, AST, and ALT < 2.5 ULN ( AST, ALT < 5.0 ULN for subjects with liver metastasis); Serum creatinine < 1.5 ULN; International normalized ratio (INR) < 1.5 and activated partial thromboplastin time (aPTT) < 1.5 ULN (except for subjects receiving anti-coagulation therapy)

Exclusion Criteria:

  1. Prior treatment with gemcitabine
  2. Three or more prior chemotherapeutic regimens for the management of primary disease
  3. Prior treatment with experimental anti-cancer agents within 4 weeks prior to Day 1 (the day the first study treatment infusions are administered)
  4. History or clinical evidence of central nervous system or brain metastases
  5. Prior treatment with Avastin or other anti-angiogenic agent
  6. Uncontrolled hypercalcemia ( >11.5 mg/dL)
  7. History of other malignancies within 5 years of Day 1, except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of breast, basal or squamous cell skin cancer
  8. History of serious systemic disease, unstable angina, myocardial infarction, stroke, transient ischemic attack,, symptoms of CHF, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal supraventricular tachycardia, are eligible) within 6 months prior to Day 1 of treatment
  9. Known HIV infection
  10. Pregnancy or lactation
  11. Major surgery, open biopsy, or significant traumatic injury within 4 weeks prior to Day 1 of treatment, or anticipation of need for major surgical procedure during the course of the study
  12. Inability to comply with study and follow-up procedures
  13. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
  14. Life expectancy of less than 12 weeks
  15. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
  16. Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
  17. Any prior history of hypertensive crisis or hypertensive encephalopathy
  18. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)
  19. Known CNS disease
  20. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
  21. Symptomatic peripheral vascular disease
  22. Evidence of bleeding diathesis or coagulopathy
  23. Any patient that the clinician considers at risk for possible GI perforation. This includes patients with clinical symptoms or signs of GI obstruction or who require parenteral nutrition, parenteral hydration, or tube feeding, and patients with evidence of free air not explained by paracentesis or recent surgical procedure.
  24. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
  25. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
  26. Serious, non-healing wound, ulcer, or bone fracture
  27. Proteinuria at screening as demonstrated by either Urine protein:creatinine (UPC) ratio ≥ 1.0 at screening OR Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
  28. Known hypersensitivity to any component of bevacizumab
  29. Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01131039

Sponsors and Collaborators
Emory University
Genentech, Inc.
Principal Investigator: Sharmila Makhija, MD Emory University

Responsible Party: Emory University Identifier: NCT01131039     History of Changes
Other Study ID Numbers: IRB00023366
AVF4314S ( Other Identifier: Other )
First Posted: May 26, 2010    Key Record Dates
Last Update Posted: December 20, 2013
Last Verified: December 2013

Keywords provided by Emory University:
Ovarian Cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors